Importantly, the use of TAK‐242‐loaded LSNAs also led to a marked reduction in pro‐inflammatory cytokines like IL‐6 and TNF‐α, suggesting that these nanoparticles can effectively modulate the immune response in sepsis.[101] Although these results are promising, we emphasize the need for further preclinical evaluations to test the efficacy of LSNAs in different sepsis models and explore optimal treatment regimens for clinical application. This evidence concerns the gene IL6 and Sepsis.